diagnostics


BinaxNOW COVID-19 Ag Card is the Beginning of the End

Abbott’s new $5, 15-minute, 50 million per month test is a game-changer This past week an eventful announcement came from Abbott Laboratories, manufacturer of several diagnostic platforms, including several already approved fro COVID-19 testing including amplification-based IDNow, and a few antibody automated systems, one prominent one being the Architect. Now […]


Sherlock Bio gets Emergency Use Authorization for CRISPR-based Diagnostics of SARS-CoV-2

It was about a year ago that I highlighted here some neat graphene technology out of Cardea Biosciences, and in that context I mentioned CRISPR-based diagnostics. (If interested, you can find the post here.) The FDA recently approved under Emergency Use Authorization (EUA) Sherlock BioSciences’ SARS-CoV-2 Rapid diagnostic (FDA EUA […]

Screencap of http://sherlock.bio announcement of EUA approval

Cardea Bio graphene CRISPR-chip being loaded

Cardea combined with CRISPR enables amplification-free digital genomics

Cardea Bio Inc. and Nanosens Innovations Inc., Keck Graduate Institute and UC Berkeley detect two deleted DMD exons in 15 minutes down to 1.7 fM sensitivity We are currently living in an exciting time in molecular diagnostics, as the fields of chemical fluorescence, optics, electronics, microfluidics, biochemistry, genomics and nanofabrication […]


Detecting cancer four years before conventional diagnosis

Announcing a big move for Dale affecting his family, his employer, his colleagues, and his friends Note: This article originally appeared on LinkedIn. The magic wand of early detection Several years ago at a meeting with sales management, someone asked a provocative question: “If you had a magic wand, what […]


NanoString’s Digital Spatial Profiling Microscope at #AGBT18

Now that another year has passed it is great to see the NanoString Digital Spatial profiling microscope near its commercial launch. The platform will be in early access to select customers in the fourth quarter of 2018, and full commercial launch in the first half of 2019. For those interested […]


Thoughts from the Association of Molecular Pathology conference #AMP2017

John Iafrede (Massachusetts General Hospital, MA) “There is a tidal wave of cell-free approaches; little performance testing; and the big question is who is going to pay for it.” This year’s Assocation for Molecular Pathology was held in Salt Lake City, Utah from November 15-18, 2017. (You can find the […]

#AMP2017